NMTC · NEUROONE MEDICAL TECHNOLOGIES Corp · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $9.2M – $10.5M | $9.47M | $9.1M | $3.45M | $1.95M | $171.17K | $178.15K | — | — | — | $0 | $742 | $773 | $1249 | $921 | $5398 | |
| — | — | — | — | — | — | -$3053 | -$7.52M | -$284.56K | -$1.4M | — | — | — | — | — | — | |
| — | $4.2M | $3.96M | $2.37M | $1.5M | $241.96K | $275.9K | — | — | — | — | — | — | — | $0 | $2138 | |
| — | $5.27M | $5.14M | $1.08M | $456.52K | -$70.79K | -$97.75K | — | — | — | — | — | — | $1249 | $921 | $3260 | |
| — | — | 56.51% | 31.27% | 23.38% | -41.36% | -54.87% | — | — | — | — | — | — | 100% | 100% | 60.39% | |
| — | $5.4M | $4.98M | $5.07M | $6.94M | $4.93M | $3.93M | $2.08M | $1.53M | $735.33K | — | — | — | — | — | — | |
| — | $6M | $5.85M | $6.5M | — | — | $6.26M | $4.75M | $4.28M | $2.34M | $32.61K | $49.59K | $36.69K | $1489 | $14.65K | $30.69K | |
| — | $7.77M | $7.38M | $7.9M | $6.93M | $6.98M | $6.26M | — | — | — | — | — | — | — | — | — | |
| — | $22.32K | $22.32K | $22.32K | $22.32K | $22.32K | $22.32K | $22.32K | $21.24K | $16.29K | — | — | — | — | — | — | |
| — | $236.88K | $261.68K | $246.79K | $199.27K | $118.62K | $80.75K | $47.61K | $27.57K | — | — | — | — | — | — | — | |
| — | $13.17M | $12.37M | $12.97M | $13.87M | $11.91M | $10.19M | $6.83M | $5.81M | $3.07M | $32.61K | $49.59K | $36.69K | $26.34K | $14.65K | $30.69K | |
| — | -$7.9M | -$4.23M | -$11.89M | -$11.96M | -$10.03M | -$10.22M | -$4.9M | -$5.81M | -$3.07M | -$32.61K | -$48.85K | -$35.91K | -$25.09K | — | — | |
| — | — | -46.46% | -344.26% | -612.32% | -5860.15% | -5735.86% | — | — | — | — | -6582.88% | -4646.05% | -2009.05% | — | — | |
| — | -$7.66M | -$3.96M | -$11.64M | -$11.76M | -$9.91M | -$10.14M | -$4.85M | -$5.79M | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | $3053 | — | — | — | — | $14.02K | — | — | -$227 | -$176 | |
| — | $77.06K | — | $125.18K | $95.76K | $31.15K | — | — | — | — | — | — | -$330 | -$5461 | — | — | |
| — | -$7.45M | -$3.61M | -$12.32M | -$11.86M | -$10M | — | -$2.02M | — | — | -$32.61K | -$62.86K | -$36.24K | -$30.55K | — | — | |
| — | — | — | — | — | — | -$271.12K | — | — | — | $0 | $0 | — | — | — | — | |
| — | -$7.45M | -$3.61M | -$12.32M | -$11.86M | -$10M | -$9.95M | -$13.64M | -$6.78M | -$5.06M | -$47.78K | -$62.86K | -$36.24K | -$30.55K | -$27.6K | -$27.6K | |
| — | — | -39.63% | -356.74% | -607.42% | -5841.95% | -5584.28% | — | — | — | — | -8472.1% | -4688.75% | -2446.28% | -2997.18% | -511.37% | |
| USD/shares | — | -$0.96 | -$0.54 | -$2.76 | -$3.90 | -$3.78 | -$5.58 | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$1.01 | -$0.54 | -$2.76 | -$3.90 | -$3.78 | -$5.58 | — | — | — | — | — | — | — | — | — |
| shares | — | — | 6.69M | 4.46M | 3.02M | 2.67M | 1.78M | 902.57K | 658.75K | 367.23K | 281.83K | 281.83K | 281.83K | 281.83K | 281.83K | 257.96K |
| shares | — | — | 6.69M | 4.46M | 3.02M | 2.67M | 1.78M | 902.57K | 658.75K | 367.23K | 281.83K | 281.83K | 281.83K | 281.83K | — | — |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 72 similar-size Medical Devices companies (of 150 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| One RF Ablation System Revenue | $9,100,000 | — |
| One RF Product Revenue | — | $300,000 |
| Product And Service Other | — | $3,500,000 |